<p>和谐生物科学控股公司（NASDAQ:HRMY - 获取免费报告）在周四市场开盘前因财报不及预期而股价跳空下跌。该股此前收于 32.78 美元，但开盘价为 28.95 美元。和谐生物科学的股票最后交易价格为 30.5760 美元，成交量为 416,439 股。</p>
<p>获取 <strong>和谐生物科学</strong> 的提醒：</p>
<p>该公司报告本季度每股收益（EPS）为 0.55 美元，低于分析师一致预期的 0.76 美元，差距为 0.21 美元。该公司本季度收入为 2.1539 亿美元，而分析师预期为 2.2084 亿美元。和谐生物科学的股本回报率为 19.86%，净利润率为 18.29%。该公司的季度收入较去年同期增长了 16.6%。在去年同期，该公司每股收益为 0.78 美元。</p>
<h2>华尔街分析师观点</h2>
<p>多家股票研究分析师对 HRMY 股票发表了看法。Needham &amp; Company LLC 将和谐生物科学的目标价从 46.00 美元下调至 44.00 美元，并在 2 月 25 日的报告中给予该股 “买入” 评级。Truist Financial 在 2 月 23 日的报告中将和谐生物科学的评级从 “买入” 下调至 “持有”。瑞银集团在 2 月 25 日的研究报告中将和谐生物科学的目标价从 46.00 美元下调至 36.00 美元，并给予该公司 “中性” 评级。瑞穗证券在 2 月 19 日的研究报告中设定了和谐生物科学的目标价为 50.00 美元。最后，Wall Street Zen 在 2 月 28 日的研究报告中将和谐生物科学的评级从 “买入” 下调至 “持有”。一位投资分析师给予该股 “强烈买入” 评级，四位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “持有”，平均目标价为 42.67 美元。</p>
<p><strong>获取我们对和谐生物科学的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>对冲基金最近对该公司的持仓进行了调整。EverSource Wealth Advisors LLC 在第四季度将其在和谐生物科学的持仓增加了 589.9%。EverSource Wealth Advisors LLC 目前拥有 752 股该公司的股票，价值 28,000 美元，此前在上个季度增持了 643 股。Allworth Financial LP 在第四季度将其在和谐生物科学的持仓增加了 286.7%。Allworth Financial LP 目前拥有 812 股该公司的股票，价值 30,000 美元，此前在上个季度增持了 602 股。Leonteq Securities AG 在第四季度购买了和谐生物科学的新头寸，价值约 30,000 美元。加拿大国家银行 FI 在第三季度购买了和谐生物科学的新头寸，价值约 40,000 美元。最后，Clearstead Advisors LLC 在第四季度将其在和谐生物科学的持仓增加了 145.9%。Clearstead Advisors LLC 目前拥有 1,178 股该公司的股票，价值 44,000 美元，此前在上个季度增持了 699 股。86.23% 的股票由机构投资者持有。</p>
<h2>和谐生物科学股票表现</h2>
<p>该公司的 50 日移动平均价格为 28.94 美元，200 日移动平均价格为 33.00 美元。该公司的流动比率为 3.60，速动比率为 3.58，债务与股本比率为 0.17。该股的市值为 17.7 亿美元，市盈率为 11.17，市盈增长比率为 0.44，贝塔值为 0.97。</p>
<h2>和谐生物科学公司简介</h2>
<p>（获取免费报告）</p>
<p>和谐生物科学控股公司是一家商业阶段的生物制药公司，专注于开发和提供针对罕见神经和内分泌疾病患者的治疗方案。公司成立于 2017 年，总部位于宾夕法尼亚州普利茅斯会议，和谐生物科学于 2020 年上市，并在纳斯达克以 HRMY 的股票代码交易。公司的使命是识别和推进能够满足现有治疗方案无法满足的患者群体的关键需求的药物。</p>
<p>该公司的旗舰产品是 WAKIX（匹托利桑），这是美国批准的首个也是唯一的组胺 H3 受体拮抗剂/反向激动剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过和谐生物科学</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在和谐生物科学吗？</h2>
<p>在你考虑和谐生物科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而和谐生物科学并不在名单上。</p>
<p>虽然和谐生物科学目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

HRMY

<p>Harmony Biosciences（纳斯达克代码：HRMY）股价下跌至 28.95 美元，此前报告的每股收益为 0.55 美元，低于预期的 0.76 美元。收入为 2.1539 亿美元，低于预测的 2.2084 亿美元。分析师已下调该股的目标价，普遍评级为 “持有”，平均目标价为 42.67 美元。机构投资者持有该股 86.23%，市值为 17.7 亿美元，市盈率为 11.17。该公司专注于罕见神经和内分泌疾病的治疗</p>

<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) shares gapped down before the market opened on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $32.78, but opened at $28.95. Harmony Biosciences shares last traded at $30.5760, with a volume of 416,439 shares traded.</p>
<div class="lb-trans"><p>和谐生物科学控股公司（NASDAQ:HRMY - 获取免费报告）在周四市场开盘前因财报不及预期而股价跳空下跌。该股此前收于 32.78 美元，但开盘价为 28.95 美元。和谐生物科学的股票最后交易价格为 30.5760 美元，成交量为 416,439 股。</p>
</div><p>Get <strong>Harmony Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>和谐生物科学</strong> 的提醒：</p>
</div><p>The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.76 by ($0.21). The company had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company's quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.78 EPS.</p>
<div class="lb-trans"><p>该公司报告本季度每股收益（EPS）为 0.55 美元，低于分析师一致预期的 0.76 美元，差距为 0.21 美元。该公司本季度收入为 2.1539 亿美元，而分析师预期为 2.2084 亿美元。和谐生物科学的股本回报率为 19.86%，净利润率为 18.29%。该公司的季度收入较去年同期增长了 16.6%。在去年同期，该公司每股收益为 0.78 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts have weighed in on HRMY shares. Needham &amp; Company LLC reduced their target price on Harmony Biosciences from $46.00 to $44.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, February 25th. Truist Financial downgraded Harmony Biosciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, February 23rd. UBS Group dropped their price target on Harmony Biosciences from $46.00 to $36.00 and set a &#34;neutral&#34; rating for the company in a research note on Wednesday, February 25th. Mizuho set a $50.00 price target on Harmony Biosciences in a research note on Thursday, February 19th. Finally, Wall Street Zen cut Harmony Biosciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $42.67.</p>
<div class="lb-trans"><p>多家股票研究分析师对 HRMY 股票发表了看法。Needham &amp; Company LLC 将和谐生物科学的目标价从 46.00 美元下调至 44.00 美元，并在 2 月 25 日的报告中给予该股 “买入” 评级。Truist Financial 在 2 月 23 日的报告中将和谐生物科学的评级从 “买入” 下调至 “持有”。瑞银集团在 2 月 25 日的研究报告中将和谐生物科学的目标价从 46.00 美元下调至 36.00 美元，并给予该公司 “中性” 评级。瑞穗证券在 2 月 19 日的研究报告中设定了和谐生物科学的目标价为 50.00 美元。最后，Wall Street Zen 在 2 月 28 日的研究报告中将和谐生物科学的评级从 “买入” 下调至 “持有”。一位投资分析师给予该股 “强烈买入” 评级，四位分析师给予 “买入” 评级，六位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的共识评级为 “持有”，平均目标价为 42.67 美元。</p>
</div><p><strong>Get Our Latest Analysis on Harmony Biosciences</strong></p>
<div class="lb-trans"><p><strong>获取我们对和谐生物科学的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its position in shares of Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company's stock worth $28,000 after acquiring an additional 643 shares in the last quarter. Allworth Financial LP raised its position in shares of Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company's stock worth $30,000 after acquiring an additional 602 shares in the last quarter. Leonteq Securities AG bought a new position in shares of Harmony Biosciences in the 4th quarter worth about $30,000. National Bank of Canada FI bought a new position in shares of Harmony Biosciences in the 3rd quarter worth about $40,000. Finally, Clearstead Advisors LLC raised its position in shares of Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company's stock worth $44,000 after acquiring an additional 699 shares in the last quarter. 86.23% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。EverSource Wealth Advisors LLC 在第四季度将其在和谐生物科学的持仓增加了 589.9%。EverSource Wealth Advisors LLC 目前拥有 752 股该公司的股票，价值 28,000 美元，此前在上个季度增持了 643 股。Allworth Financial LP 在第四季度将其在和谐生物科学的持仓增加了 286.7%。Allworth Financial LP 目前拥有 812 股该公司的股票，价值 30,000 美元，此前在上个季度增持了 602 股。Leonteq Securities AG 在第四季度购买了和谐生物科学的新头寸，价值约 30,000 美元。加拿大国家银行 FI 在第三季度购买了和谐生物科学的新头寸，价值约 40,000 美元。最后，Clearstead Advisors LLC 在第四季度将其在和谐生物科学的持仓增加了 145.9%。Clearstead Advisors LLC 目前拥有 1,178 股该公司的股票，价值 44,000 美元，此前在上个季度增持了 699 股。86.23% 的股票由机构投资者持有。</p>
</div><h2>Harmony Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>和谐生物科学股票表现</h2>
</div><p>The company has a 50-day moving average price of $28.94 and a two-hundred day moving average price of $33.00. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.77 billion, a P/E ratio of 11.17, a price-to-earnings-growth ratio of 0.44 and a beta of 0.97.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 28.94 美元，200 日移动平均价格为 33.00 美元。该公司的流动比率为 3.60，速动比率为 3.58，债务与股本比率为 0.17。该股的市值为 17.7 亿美元，市盈率为 11.17，市盈增长比率为 0.44，贝塔值为 0.97。</p>
</div><h2>Harmony Biosciences Company Profile</h2>
<div class="lb-trans"><h2>和谐生物科学公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.</p>
<div class="lb-trans"><p>和谐生物科学控股公司是一家商业阶段的生物制药公司，专注于开发和提供针对罕见神经和内分泌疾病患者的治疗方案。公司成立于 2017 年，总部位于宾夕法尼亚州普利茅斯会议，和谐生物科学于 2020 年上市，并在纳斯达克以 HRMY 的股票代码交易。公司的使命是识别和推进能够满足现有治疗方案无法满足的患者群体的关键需求的药物。</p>
</div><p>The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.</p>
<div class="lb-trans"><p>该公司的旗舰产品是 WAKIX（匹托利桑），这是美国批准的首个也是唯一的组胺 H3 受体拮抗剂/反向激动剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Harmony Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过和谐生物科学</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Harmony Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在和谐生物科学吗？</h2>
</div><p>Before you consider Harmony Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑和谐生物科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而和谐生物科学并不在名单上。</p>
</div><p>While Harmony Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然和谐生物科学目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Harmony Biosciences（纳斯达克股票代码：HRMY）因业绩不佳导致股价跳空低开